DNA-Binding Small Molecules as Inhibitors of Transcription Factors

Medicinal Research Reviews

Volumn 33, Issue 4, 2013, Pages 823-846

  Leung, Chung Hang ^a,b   Chan, Daniel Shiu Hin ^c   Ma, Victor Pui Yan ^c   Ma, Dik Lung ^c  

^a University of Macau   (Macao)

^b UNIVERSITY OF MACAU   (Macao)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Groove binding; Inhibitor; Intercalation; Small molecule; Transcription factor

Indexed keywords

DB293; DNA; DNA BINDING SMALL MOLECULE; ECHINOMYCIN; FLAVOPIRIDOL; GWL 78; MITHRAMYCIN A; MLN944; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; GEL MOBILITY SHIFT ASSAY; HUMAN; NONHUMAN; PROTEIN DNA INTERACTION; TRANSCRIPTION INITIATION;

EID: 84878656671     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21266     Document Type: Article

References (121)

1. Pabo CO, Sauer RT. Transcription factors: Structural families and principles of DNA recognition. Annu Rev Biochem 1992;61(1):1053-1095.
2. Wang K, Wan Y-JY. Nuclear receptors and inflammatory diseases. Exp Biol Med 2008;233(5):496-506.
3. Latchman DS. Transcription-factor mutations and disease. New Engl J Med 1996;334(1):28-33.
4. Babu MM, Luscombe NM, Aravind L, Gerstein M, Teichmann SA. Structure and evolution of transcriptional regulatory networks. Curr Opin Struct Biol 2004;14(3):283-291.
5. Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2(10):740-749.
6. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005;41(16):2462-2478.
7. Pratap J, Lian JB, Stein GS. Metastatic bone disease: Role of transcription factors and future targets. Bone 2011;48(1):30-36.
8. Santiago-Walker A, Herlyn M. The ups and downs of transcription factors in melanoma. J Natl Cancer Inst 2010;102(15):1103-1104.
9. Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, Serafina Ristaldi M, Marzella R, Rocchi M, Nicolino M, Lienhardt-Roussie A, Nivelon A, Verloes A, Schlessinger D, Gasparini P, Bonneau D, Cao A, Pilia G. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001;27(2):159-166.
10. Kozlowski K, Walter MA. Variation in residual PITX2 activity underlies the phenotypic spectrum of anterior segment developmental disorders. Hum Mol Genet 2000;9(14):2131-2139.
11. Dattani M, Robinson I. The molecular basis for developmental disorders of the pituitary gland in man. Clin Genet 2000;57(5):337-346.
12. Chang H-C, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, Jabeen R, McKinley C, Ahyi A-N, Han L, Nguyen ET, Robertson MJ, Perumal NB, Tepper RS, Nutt SL, Kaplan MH. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010;11(6):527-534.
13. Koch MA, Tucker-Heard Gs, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009;10(6):595-602.
14. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-[kappa]B as the matchmaker. Nat Immunol 2011;12(8):715-723.
15. Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, Beg AA, Tergaonkar V, Chandel NS, Franzoso G. NF-[kappa]B controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol 2011;13(10):1272-1279.
16. Lee TI, Young RA. Transcription of eukaryotic protein-coding genes. Annu Rev Genet 2000;34(1):77-137.
17. Kornberg RD. The molecular basis of eukaryotic transcription. Proc Natl Acad Sci USA 2007;104(32):12955-12961.
18. Bourbon H-M, Aguilera A, Ansari AZ, Asturias FJ, Berk AJ, Bjorklund S, Blackwell TK, Borggrefe T, Carey M, Carlson M, Conaway JW, Conaway RC, Emmons SW, Fondell JD, Freedman LP, Fukasawa T, Gustafsson CM, Han M, He X, Herman PK, Hinnebusch AG, Holmberg S, Holstege FC, Jaehning JA, Kim Y-J, Kuras L, Leutz A, Lis JT, Meisterernest M, Naar AM, Nasmyth K, Parvin JD, Ptashne M, Reinberg D, Ronne H, Sadowski I, Sakurai H, Sipiczki M, Sternberg PW, Stillman DJ, Strich R, Struhl K, Svejstrup JQ, Tuck S, Winston F, Roeder RG, Kornberg RD. A unified nomenclature for protein subunits of mediator complexes linking transcriptional regulators to RNA polymerase II. Mol cell 2004;14(5):553-557.
19. Kornberg RD. Mediator and the mechanism of transcriptional activation. Trends Biochem Sci 2005;30(5):235-239.
20. Fliri AF, Loging WT, Volkmann RA. Drug effects viewed from a signal transduction network perspective. J Med Chem 2009;52(24):8038-8046.
21. Thorsten B. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol 2008;12(4):464-471.
22. Majmudar CY, Mapp AK. Chemical approaches to transcriptional regulation. Curr Opin Chem Biol 2005;9(5):467-474.
23. Arndt H-D. Small molecule modulators of transcription. Angew Chem Int Ed 2006;45(28):4552-4560.
24. Koehler AN. A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol 2010;14(3):331-340.
25. Madan Babu M, Teichmann SA. Evolution of transcription factors and the gene regulatory network in Escherichia coli. Nucleic Acids Res 2003;31(4):1234-1244.
26. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450(7172):1001-1009.
27. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed 2005;44(27):4130-4163.
28. Gniazdowski M, Denny WA, Nelson SM, Czyz M. Transcription factors as targets for DNA-interacting drugs. Curr Med Chem 2003;10(11):909-924.
29. Gniazdowski M, Denny WA, Nelson SM, Czyz M. Effects of anticancer drugs on transcription factor-DNA interactions. Expert Opin Ther Targets 2005;9(3):471-489.
30. Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nat Protocols 2007;2(8):1849-1861.
31. Tullius TD. Physical studies of protein-DNA complexes by footprinting. Annu Rev Biophys Biophys Chem 1989; 18(1):213-217.
32. Nunn CM, Neidle S. Sequence-dependent drug binding to the minor groove of DNA: Crystal structure of the DNA dodecamer d(CGCAAATTTGCG)2 complexed with propamidine. J Med Chem 1995;38(13):2317-2325.
33. Suh D, Chaires JB. Criteria for the mode of binding of DNA binding agents. Bioorg Med Chem 1995;3(6):723-728.
34. Williams AK, Dasilva SC, Bhatta A, Rawal B, Liu M, Korobkova EA. Determination of the drug-DNA binding modes using fluorescence-based assays. Anal Biochem 2012;422(2):66-73.
35. Collins JG, Sleeman AD, Aldrich-Wright JR, Greguric I, Hambley TW. A 1H NMR study of the DNA binding of ruthenium(II) polypyridyl complexes. Inorg Chem 1998;37(13):3133-3141.
36. Wang J, Lu J, Gu G, Liu Y. In vitro DNA-binding profile of transcription factors: Methods and new insights. J Endocrinol 2011;210(1):15-27.
37. Neidle S. Principles of Small Molecule-DNA Recognition. Principles of Nucleic Acid Structure. New York, USA: Academic Press; 2008. p 132-203.
38. Xie Y, Tam VK, Tor Y. The Interactions of Small Molecules with DNA and RNA. In: Mayer G, editor. The Chemical Biology of Nucleic Acids. Chichester, UK: John Wiley & Sons, Ltd; 2010. p 115-140.
39. Jonathan B C. Drug-DNA interactions. Curr Opin Struct Biol 1998;8(3):314-320.
40. Reversible Small Molecule-Nucleic Acid Interactions. In: Blackburn GM, Gait MJ, Loakes D, Williams DM, editors. Nucleic Acids in Chemistry and Biology. 3rd ed. Cambridge, UK: RSC publishing; 2006. p 341-382.
41. Dai J, Punchihewa C, Mistry P, Ooi AT, Yang D. Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. J Biol Chem 2004;279(44):46096-46103.
42. Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, Okiji S, Baguley BC, Denny WA, Charlton PA. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anti-Cancer Drugs 2001;12(4):359-367.
43. Gamage SA, Spicer JA, Finlay GJ, Stewart AJ, Charlton P, Baguley BC, Denny WA. Dicationic bis(9-methylphenazine-1-carboxamides): Relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem 2001;44(9):1407-1415.
44. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3(11):859-868.
45. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2006;26(1):1-10.
46. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007;407:cm8.
47. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: A novel target for cancer therapy. Anti-Cancer Drugs 2005;16(9):901-909.
48. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009;19(1):12-16.
49. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009;29(5):625-634.
50. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005;65(19):9047-9055.
51. Van Dyke M, Dervan P. Echinomycin binding sites on DNA. Science 1984;225(4667):1122-1127.
52. Wadler S, Tenteromano L, Cazenave L, Sparano JA, Greenwald ES, Rozenblit A, Kaleya R, Wiernik PH. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol 1994;34(3):266-269.
53. Gradishar WJ, Vogelzang NJ, Kilton LJ, Leibach SJ, Rademaker AW, French S, Benson AB. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. Invest New Drugs 1995;13(2):171-174.
54. Swami M. Transcription factors: MYC matters. Nat Rev Cancer 2010;10(12):812-813.
55. Schneider BP, Sledge GW. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Prac Oncol 2007;4(3):181-189.
56. Lee YK, Isham CR, Kaufman SH, Bible KC. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther 2006;5(1):138-148.
57. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002;296(5573):1653-1655.
58. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
59. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009;9(11):798-809.
60. Bible KC, Bible RH, Kottke TJ, Svingen PA, Xu K, Pang Y-P, Hajdu E, Kaufmann SH. Flavopiridol binds to duplex DNA. Cancer Res 2000;60(9):2419-2428.
61. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379(6566):645-648.
62. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34(2):155-166.
63. Odom DT, Parker CS, Barton JK. Site-specific inhibition of transcription factor binding to DNA by a metallointercalator. Biochemistry 1999;38(16):5155-5163.
64. Talib J, Beck JL, Urathamakul T, Nguyen CD, Aldrich-Wright JR, Mackay JP, Ralph SF. A mass spectrometric investigation of the ability of metal complexes to modulate transcription factor activity. Chem Commun 2009(37):5546-5548.
65. Scott E, Simon M, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994;265(5178):1573-1577.
66. Ihmels H, Faulhaber K, Viola G, Schmuck C. Evaluation of the DNA-Binding Properties of Cationic Dyes by Absorption and Emission Spectroscopy. In: Schmuck C, Wennemers H, editors. Highlights in Bioorganic Chemistry. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA; 2005. p 172-190.
67. Baraldi PG, Bovero A, Fruttarolo F, Preti D, Tabrizi MA, Pavani MG, Romagnoli R. DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev 2004;24(4):475-528.
68. Neidle S. DNA minor-groove recognition by small molecules. Nat Prod Rep 2001;18(3):291-309.
69. Wemmer DE, Dervan PB. Targeting the minor groove of DNA. Curr Opin Struct Biol 1997;7(3):355-361.
70. Turner PR, Denny WA. The genome as a drug target: Sequence specific minor groove binding ligands. Curr Drug Targets 2000;1(1):1-14.
71. Dervan PB. Molecular recognition of DNA by small molecules. Bioorg Med Chem 2001;9(9):2215-2235.
72. Wade WS, Mrksich M, Dervan PB. Design of peptides that bind in the minor groove of DNA at 5′-(A, T)G(A, T)C(A, T)-3′ sequences by a dimeric side-by-side motif. J Am Chem Soc 1992;114(23):8783-8794.
73. Chenoweth DM, Dervan PB. Allosteric modulation of DNA by small molecules. Proc Natl Acad Sci USA 2009;106(32):13175-13179.
74. Pelton JG, Wemmer DE. Structural characterization of a 2:1 distamycin A.d(CGCAAATTGGC) complex by two-dimensional NMR. Proc Natl Acad Sci USA 1989;86(15):5723-5727.
75. Mrksich M, Wade WS, Dwyer TJ, Geierstanger BH, Wemmer DE, Dervan PB. Antiparallel side-by-side dimeric motif for sequence-specific recognition in the minor groove of DNA by the designed peptide 1-methylimidazole-2-carboxamide netropsin. Proc Natl Acad Sci USA 1992;89(16):7586-7590.
76. Trauger JW, Baird EE, Dervan PB. Recognition of DNA by designed ligands at subnanomolar concentrations. Nature 1996;382(6591):559-561.
77. Swalley SE, Baird EE, Dervan PB. Effects of γ-turn and β-tail amino acids on sequence-specific recognition of DNA by hairpin polyamides. J Am Chem Soc 1999;121(6):1113-1120.
78. Wang CCC, Ellervik U, Dervan PB. Expanding the recognition of the minor groove of DNA by incorporation of β-alanine in hairpin polyamides. Bioorg Med Chem 2001;9(3):653-657.
79. Hsu CF, Phillips JW, Trauger JW, Farkas ME, Belitsky JM, Heckel A, Olenyuk BZ, Puckett JW, Wang CCC, Dervan PB. Completion of a programmable DNA-binding small molecule library. Tetrahedron 2007;63(27):6146-6151.
80. Dervan PB, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol 2003;13(3):284-299.
81. Fechter EJ, Dervan PB. Allosteric inhibition of protein-DNA complexes by polyamide-intercalator conjugates. J Am Chem Soc 2003;125(28):8476-8485.
82. Shinohara K-i, Narita A, Oyoshi T, Bando T, Teraoka H, Sugiyama H. Sequence-specific gene silencing in mammalian cells by alkylating pyrrole-imidazole polyamides. J Am Chem Soc 2004;126(16):5113-5118.
83. Hsu CF, Dervan PB. Quantitating the concentration of Py-Im polyamide-fluorescein conjugates in live cells. Bioorg Med Chem let 2008;18(22):5851-5855.
84. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Res 2007;35(2):363-370.
85. Olenyuk BZ, Zhang G-J, Klco JM, Nickols NG, Kaelin WG, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA 2004;101(48):16768-16773.
86. Viger A, Dervan PB. Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site. Bioorg Med Chem 2006;14(24):8539-8549.
87. Kageyama Y, Sugiyama H, Ayame H, Iwai A, Fujii Y, Eric Huang L, Kizaka-Kondoh S, Hiraoka M, Kihara K. Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol 2006;45(3):317-324.
88. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. New Engl J Med 2000;342(18):1350-1358.
89. Matsuda H, Fukuda N, Ueno T, Tahira Y, Ayame H, Zhang W, Bando T, Sugiyama H, Saito S, Matsumoto K, Mugishima H, Serie K. Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-β1 promoter for treatment of progressive renal diseases. J Am Soc Nephrol 2006;17(2):422-432.
90. Matsuda H, Fukuda N, Ueno T, Katakawa M, Wang X, Watanabe T, Matsui S-I, Aoyama T, Saito K, Bando T, Matsumoto Y, Nagase H, Matsumoto K, Sugiyama H. Transcriptional inhibition of progressive renal disease by gene silencing pyrrole-imidazole polyamide targeting of the transforming growth factor-[beta]1 promoter. Kidney Int 2011;79(1):46-56.
91. Yao E-H, Fukuda N, Ueno T, Matsuda H, Matsumoto K, Nagase H, Matsumoto Y, Takasaka A, Serie K, Sugiyama H, Sawamura T. Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury. Hypertension 2008;52(1):86-92.
92. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002;95(1):89-100.
93. Hochhauser D, Kotecha M, O'Hare C, Morris PJ, Hartley JM, Taherbhai Z, Harris D, Forni C, Mantovani R, Lee M, Hartley JA. Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide. Mol Cancer Ther 2007;6(1):346-354.
94. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G. Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10(3):191-202.
95. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
96. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, Mills IG. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007;8(9):871-878.
97. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci USA 2007;104(25):10418-10423.
98. Mao H-L, Zhu Z-Q, Chen CD. The androgen receptor in hormone-refractory prostate cancer. Asian J Androl 2008;11(1):69-73.
99. Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer CA, Lezon-Geyda K, Wheeler J, Harki DA, Muzikar KA, Stolper DA, Dervan PB, Perkins AS. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry 2011;50(48):10431-10441.
100. Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 1991;11(5):2665-2674.
101. Lee T-J, Jung EM, Lee JT, Kim S, Park J-W, Choi KS, Kwon TK. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006;5(11):2737-2746.
102. Sastry M, Patel DJ. Solution structure of the mithramycin dimer-DNA complex. Biochemistry 1993;32(26):6588-6604.
103. Kotecha M, Kluza J, Wells G, O'Hare CC, Forni C, Mantovani R, Howard PW, Morris P, Thurston DE, Hartley JA, Hochhauser D. Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78. Mol Cancer Ther 2008;7(5):1319-1328.
104. Wells G, Martin CRH, Howard PW, Sands ZA, Laughton CA, Tiberghien A, Woo CK, Masterson LA, Stephenson MJ, Hartley JA, Jenkins TC, Shnyder SD, Loadman PM, Waring MJ, Thurston DE. Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates. J Med Chem 2006;49(18):5442-5461.
105. Peixoto P, Liu Y, Depauw S, Hildebrand M-P, Boykin DW, Bailly C, Wilson WD, David-Cordonnier M-H. Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication. Nucleic Acids Res 2008;36(10):3341-3353.
106. Gil-Puig C, Seoane S, Blanco M, Macia M, Garcia-Caballero T, Segura C, Perez-Fernandez R. Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation. Eur J Endocrinol 2005;153(2):335-344.
107. Cook AL, Sturm RA. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res 2008;21(6):611-626.
108. Bailly C, Tardy C, Wang L, Armitage B, Hopkins K, Kumar A, Schuster GB, Boykin DW, Wilson WD. Recognition of ATGA sequences by the unfused aromatic dication DB293 forming stacked dimers in the DNA minor groove. Biochemistry 2001;40(33):9770-9779.
109. Moser H, Dervan P. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 1987;238(4827):645-650.
110. Thuong NT, Hélène C. Sequence-specific recognition and modification of double-helical DNA by oligonucleotides. Angew Chem Int Ed 1993;32(5):666-690.
111. Duval-Valentin G, Thuong NT, Hélène C. Specific inhibition of transcription by triple helix-forming oligonucleotides. Proc Natl Acad Sci USA 1992;89(2):504-508.
112. Faria M, Giovannangeli C. Triplex-forming molecules: From concepts to applications. J Gene Med 2001;3(4):299-310.
113. Singhal G, Akhter MZ, Stern DF, Gupta SD, Ahuja A, Sharma U, Jagannathan NR, Rajeswari MR. DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma. Cancer Gene Ther 2011;18(7):520-530.
114. Knauert MP, Glazer PM. Triplex forming oligonucleotides: Sequence-specific tools for gene targeting. Hum Mol Genet 2001;10(20):2243-2251.
115. Simon P, Cannata F, Concordet J-P, Giovannangeli C. Targeting DNA with triplex-forming oligonucleotides to modify gene sequence. Biochimie 2008;90(8):1109-1116.
116. Raja NS, Nair BU. Chromium(III) complexes inhibit transcription factors binding to DNA and associated gene expression. Toxicology 2008;251(1-3):61-65.
117. Levina A, Lay PA. Chemical properties and toxicity of chromium(III) nutritional supplements. Chem Res Toxicol 2008;21(3):563-571.
118. Wang P, Leung C-H, Ma D-L, Sun RW-Y, Yan S-C, Chen Q-S, Che C-M. Specific blocking of CREB/DNA binding by cyclometalated platinum(II) complexes. Angew Chem Int Ed 2011;50(11):2554-2558.
119. Conkright MD, Montminy M. CREB: The unindicted cancer co-conspirator. Trends Cell Biol 2005;15(9):457-459.
120. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: Implications for targeting transcription factors for cancer therapy. Clin Cancer Res 2009;15(8):2583-2587.
121. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol 2007;2(8):561-571.